

Medical Policy Manual

Draft Revised Policy: Do Not Implement

Anifrolumab-fnia (Saphnelo®)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.

Limitations of Use

The efficacy of Saphnelo has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of Saphnelo is not recommended in these situations.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Initial requests: Medical records (e.g., chart notes, lab reports) documenting the presence of autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm, antiphospholipid antibodies, complement proteins).
- B. Continuation requests: Medical records (e.g., chart notes, lab reports) documenting disease stability or improvement.

III. EXCLUSIONS

Coverage will not be provided for members with any of the following exclusions:

- A. Severe active lupus nephritis in a member initiating therapy with Saphnelo.
- B. Severe active central nervous system (CNS) lupus (including seizures that are attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention ~~within 60 days~~ before initiation of anifrolumab) in a member initiating therapy with Saphnelo.
- C. Member is using Saphnelo in combination with other biologics.

IV. CRITERIA FOR INITIAL APPROVAL

Systemic lupus erythematosus (SLE)

Medical Policy Manual

Draft Revised Policy: Do Not Implement

Authorization of 12 months may be granted for treatment of active SLE when all of the following criteria are met:

- A. Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm, antiphospholipid antibodies, complement proteins).
- B. The member is receiving a stable standard treatment for SLE with any of the following (alone or in combination):
 1. Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone)
 2. Antimalarials (e.g., hydroxychloroquine)
 3. Immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide)

V. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section IV who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Saphnelo [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; **December 2023**.
2. Fanouriakis A, Kostopoulou M, Alunno A, et al. **2023** Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. *Ann Rheum Dis*. **2024;83:15-29**.
3. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78:1151-1159.
4. Gordon C, Amissah-Arthru MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)*. 2018; 57(1):e1-e45.
5. Petri M, Orbai A-M, Alarcon GS, et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheum*. 2012; 64:2677-2686. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409311/>. Accessed **January 10, 2024**.

EFFECTIVE DATE

ID_CHS